Item 7.01. Regulation FD Disclosure

On April 25, 2022, Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the "Company") entered into definitive agreements to form a joint venture, Visirna Therapeutics, Inc. ("Visirna"), with Vivo Capital ("Vivo") to expand the reach of innovative medicines in Greater China. In connection with the formation of the joint venture, the Company licensed to Visirna the exclusive rights to develop and commercialize four of Arrowhead's investigational RNA interference (RNAi) therapeutic candidates for cardiometabolic diseases in mainland China, Hong Kong, Macau, and Taiwan.

Funds affiliated with Vivo provided initial funding of $60 million to Visirna. The Company has a majority stake in Visirna following this initial funding and is further eligible to receive potential royalties on commercial sales.

On April 25, 2022, the Company issued a press release in connection with the transaction, which is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits

Exhibit
  No.       Description

99.1          Press Release*

104         Cover Page Interactive File (the cover page tags are embedded within
            the Inline XBRL document).



* Furnished herewith

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses